

Extractables Testing of Aluminosilicate and Borosilicate Glass Containers

Daniel Kramer, Robert Schaut, PhD, Ela Bakowska, Misty Riesbeck, Alex Thomas, Steven Tietje, Corning Incorporated

When it comes to required extraction studies (1) for new glass compositions that are starting to enter the parenteral packaging market, manufacturers naturally have questions about the suitability of these new products. One extraction study potentially answers these questions.

Extraction studies are necessary because glass containers, which are frequently considered inert, react with aqueous solutions at relatively low rates in most parenteral drug applications.

Extraction methods for glass assess the durability of the container surface to any number of solution chemistries, often accelerated using elevated temperatures. Solution analysis then quantifies the amount of glass constituents that have reacted or dissolved from the container into solution.

Compendial chapters offer methods to quantify the hydrolytic resistance of glass containers for pharmaceutical packaging (2–4). These methods involve an accelerated treatment (e.g., autoclave) of containers filled with pure water followed by titration of the reacted solution (5). A separate, quantitative analysis of the nontitrated, post-autoclave solution provides the concentrations of elements extracted from the interior of the glass container. While not an exhaustive representation of container extracts from all conditions (3), these are perhaps the most commonly referenced set of extraction conditions.

Although compendial chapters group results by nominal container volume and set numerous unique limits, glass corrosion literature has demonstrated that extracted solution concentrations are a result of glass surface area and true solution volume

diluting the response (6). It is therefore helpful to compare extract concentrations from dissimilar container shapes by normalizing the results to the glass surface area-to-solution volume ratio (SA/V).

The chemical durability of glass containers (i.e., resistance to corrosion) depends on many factors, including bulk composition, changes in surface chemistry produced during manufacturing (e.g., converting), the solution chemistry of reaction and the time and temperature of exposure (3,7). For many years, glass vials used for parenteral packaging were mostly composed of borosilicate composition; durable, boron-free aluminosilicate containers have been introduced for use in parenteral packaging (8). Chemical strengthening with molten salt is used to improve the mechanical performance of borosilicate and aluminosilicate glass packaging components.

In this study, the aluminosilicate containers used were chemically strengthened. Regarding glass composition, hydrolytic resistance of silicate glasses generally depends on the relative amounts of oxides identified as network formers (e.g., SiO₂, B₂O₃), intermediates (e.g., Al₂O₃), and alkali/alkaline-earth modifiers (e.g., Na₂O, K₂O, CaO, MgO). In general, higher-silica glasses exhibit greater chemical durability, additions of alumina can improve durability in certain cases, and the addition of excess alkali

oxides and boron $(R_2O + B_2O_3)$ can have a negative effect on hydrolytic resistance (7). Other extractables may be a result of property modifiers (e.g., oxides of barium or iron) or fining agents (e.g., oxides of arsenic or tin) used in glass manufacturing, and from impurities in raw materials. The glass containers used in this study were commercially available borosilicate and aluminosilicate products designed specifically for use in primary pharmaceutical packaging. All three container types used in this study meet the Type I performance criteria (titration limit) for the surface hydrolytic test outlined in USP <660> Containers-Glass. The major components in each glass are outlined in **Table 1** below.

Although both glass tubing and/or formed containers may be used to characterize materials of construction, an extractables analysis of a primary packaging component must include testing of the final containers such as vials ready for drug fill. Containers that are molded or converted must be included in an extractables analysis in order to evaluate effects of the tube-to-vial converting process which can produce chemical heterogeneities across the container surface. These regions of variable chemical composition may lead to differences in chemical durability, which are undesirable, and these effects can only be evaluated in the final container.

 Table 1
 Oxide Components of Glasses Studied

Glass Type	SiO ₂	Al ₂ O ₃	B ₂ O ₃	Na ₂ O	K ₂ O	CaO	MgO
Aluminosilicate A	1	1	×	✓	✓	1	1
Borosilicate B	1	1	1	1	×	1	×
Borosilicate C	1	1	1	1	1	1	1

 \checkmark = present in bulk glass, × = not present

In certain cases, such chemical heterogeneities in borosilicate glass containers have been shown to produce delamination of silica-rich lamellae from the surface into the drug product (9,10). Often, these heterogeneities are caused by the volatilization of alkali and boron from the glass during the converting process and subsequent deposition resulting in a surface enriched in excess alkali and boron.

The vials used in this study were converted from size matched tubing and were converted to the same overall dimensions. The tubes were suitably closed with PTFE and silicone stoppers to hold liquid. Vials and tubes were filled with ultrapure water, and autoclaved with a hold of one hour at 121°C according to procedures outlined in USP chapter <660> and ISO 4802




Figure 1 Ratio of Total Extractables for Vials and Tubes of Three Different Glasses (*The higher ratio for the borosilicate samples indicates a greater change in surface chemistry during the tube-to-vial converting process. Concentrations of extractables have been normalized for differences in SA/V.)*




Figure 2 Ratio of Extracted Alkali+Boron for Vials and Tubes of Three Different Glasses

(2,4,6). The reacted solution samples were then analyzed quantitatively by ICP-MS. Concentrations were normalized for wetted surface area-to-fill volume to account for differences in container geometry.

To illustrate the effects of the converting process on chemical durability, extractables of formed vials and tubing are compared in Figure 1 and Figure 2. For both borosilicate vials tested, the total concentration of extractables was greater than that of the parent glass tubing (even when normalized for differences in SA/V between the vials and tubing). This increase in total extractables after converting is due to changes in surface chemistry from the converting process. In **Figure 2**, only the relative concentrations of extracted alkali and boron are compared, and the vial-totube ratios of these extracted species were greater for the Borosilicate B and Borosilicate C containers/tubes than for the Aluminosilicate A containers/tubes.




Figure 3 Extractables Profiles for Three Vial Types Measured by ICP-MS and Normalized by SA/V (Concentrations greater than the chosen scale are labeled individually.)




Figure 4 Total Sum of Extractables for Three Vial Types Measured by ICP-MS and Normalized for SA/V

The extractables profiles for size-matched vials are presented in Figure 3 and include only extracted elements with a reported concentration greater than 0.01 ppm (µg/ mL). A comparison of the total amount of extractables for each vial type is presented in **Figure 4**. The Aluminosilicate A containers exhibited lower concentrations of extracted aluminum and silicon than the (aluminumcontaining) borosilicate containers. If the extracted amount of silicon, boron and aluminum is considered as a measure of breakdown of the glass network during corrosion, the extractables profile for Borosilicate C indicates it is the least chemically durable of the three container types tested. Alkali (Na, K) and boron components in glass have significantly higher dissolution rate in water compared to other glass components, so it is helpful to consider their extracted concentrations together rather than separately (7). The data in Figure 3 shows that extracted Na+K+B is greater for both Borosilicate B and Borosilicate C than for Aluminosilicate A.

Despite a greater amount of extracted potassium for Aluminosilicate A, the comparison of total levels of extracted alkali+boron indicates that the Borosilicate B and Borosilicate C containers demonstrate a weaker resistance to corrosion in water compared to Aluminosilicate A. The Aluminosilicate A vials exhibited the lowest concentration of total extractables, overall.

In short, the extractables analysis shows Aluminosilicate A to have a high degree of chemical durability and more uniform surface chemistry after converting, further reinforcing its suitability for use in parenteral packaging applications.

[Editor's Note: The authors' company will be exhibiting at the *2018 PDA Annual Meeting.*]

References

- Guidance for Industry: Container Closure Systems for Packaging Human Drugs and Biologics, May 1999, U.S. Food and Drug Administration.
- Chapter <660> "Containers- Glass", Physical Tests, USP 40, United States Pharmacopeia.
- Chapter <1660> "Evaluation of the Inner Surface Durability of Glass Containers", General Chapters, USP 40, United States Pharmacopeia.

Millipore®

Filtration, Separation & Preparation

Your goal is

ZERO

POSITIVES

so is ours





Be assured that we offer the quality TSB that you are looking for in your aseptic process simulation.

When you are performing a media fill test, the last thing that should be on your mind is if your TSB media is going to affect your validated process.

Every lot our irradiated media is tested for Sterility, absence of Mycoplasma, and comes in the high-performing granulated format. Along with the cleanroom ready triple-wrapped packaging, the advantages are clear.

EMDMillipore.com/media-fill

Feature	Impact	
Triple bagged and ready for cleanroom use	Three layers of protection allow you to add directly to production vessels and delivery systems.	
Irradiation process using 48–68 kGy gamma	Robust validated process ensures that media related positives are eliminated from your aseptic process simulation. The irradiation process inactivates any viable bacteria, yeast, mold, spores and Mycoplasma.	
Every lot is Mycoplasma tested	Validated PCR technology QC testing process for Mycoplasma detection to ensure absence of this difficult contaminant.	
Growth promotion tested to meet ISO® standard 11133	 Growth promotion and sterility tested exceeding expectations of USP/EP standards 	
	– Produced and tested according to ISO standard 11133.	
Detailed certificates of origin and suitability	Complete traceability documentation for compliance with BSE/TSE requirements.	
Excellent filterability and solubility	Reduces preparation time and prolongs filter life during media fills when compared to traditional powdered media, thus saving time and money by reducing filter changes.	
Exclusive granulated format	Reduction of dust during preparation, lower risk to your operators. Easier handling and less dust to adhere to equipment.	





- 4. Chapter 3.2.1 "Glass Containers for Pharmaceutical Use", European Pharmacopeia.
- 5. ISO 4802:2016, "Glassware Hydrolytic resistance of the interior surfaces of glass containers".
- 6. Ebert, W.L. "The Effects of the Glass Surface Area/Solution Volume Ratio on Glass Corrosion: A Critical Review," Argonne National Laboratory, March 1995.
- 7. Condradt, R. "Chemical Durability of Oxide Glasses in Aqueous Solutions: A Review." Journal of the American Ceramic Society 91 (2008): 728-735.
- 8. Schaut, R.A., et al. "A New Glass Option for Parenteral Packaging." PDA Journal of Pharmaceutical Science and Technology 68 (2014): 527-534
- 9. Schaut, R.A., and Weeks, W.P. "Historical Review of Glasses Used for Parenteral Packaging." PDA Journal of Pharmaceutical Science and Technology 71 (2017): 279-296.
- 10. Swift, R. "Glass containers for parenteral products." In Pharmaceutical Dosage Forms -Parenteral Medications, Third Edition, edited by Sandeep Nema and John D. Ludwig, 287-304. Boca Raton, FL: CRC Press, 2012.

About the Authors

Daniel Kramer is a glass development scientist at Corning Incorporated working on glass surfaces and chemical durability of products for the pharmaceutical market.




Robert A. Schaut, PhD, is a Senior Research Associate in the Glass Research department of the Science & Technology division at Corning Incorporated, specializing in the study of chemical and physical properties of glass surfaces.

Ela Bakowska, PhD, works within Corning's Characterization Sciences department within the Science & Technology division.



Misty Riesbeck works within Corning's Characterization Sciences department within the Science & Technology division.











pda.org/2018VisualIG

2018 PDA Visual Inspection Interest Group Workshop

At the 2018 PDA Visual Inspection Interest Group Workshop, attendees can participate in extended discussion on hot topics in the field, focusing on areas of interest and concern and exploring possible solutions to challenging issues.

Attendees are invited to suggest, in advance of the Workshop, potential topics for discussion.

This Workshop will focus on:

- Identifying unique testing requirements for difficult to inspect products found in USP <790>, such as suspensions, freeze dried powders, colored solutions, biopharmaceuticals with inherent particles and those products in non-transparent containers
- Developing practical implementation strategies for automated inspection methods
- Understanding the current proposal to revise EC Annex 1, including the proposed requirements for visual inspection and container integrity testing

To ensure an effective environment for interactive discussions, attendance to each meeting is limited, so make sure to reserve your spot early.

To learn more and register, please visit pda.org/2018VisualIG

Extend your learning experience by attending PDA's An Introduction to Visual Inspection course, Apr. 26-27. This course will cover the fundamentals of visual inspection and their application to injectable products.

To learn more and register, please visit pda.org/2018VisualIntro



April 25, 2018 | Bethesda, MD **#PDAVISUAL**

